ArriVent BioPharma, Inc. (AVBP) AI Stock Analysis

• Market Cap: $948.23M
• Dividend Yield: N/A
• Average Volume (3M): 434.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.99
• Revenue Growth: N/A
• EPS Growth: -75.31%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 41,281,360
• 10 Day Avg. Volume: 278,060
• 30 Day Avg. Volume: 434,916
• PEG Ratio: -0.58
• Price to Book (P/B): 3.25
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.94
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -5.33
• 1Y Price Target: $42.00
• Price Target Upside: 82.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -3.95
• Revenue Forecast (FY): $111.11K

• Rating: 45 Neutral
• Price Target: $22.50 ▼(-2.05% Downside)
• Action: Upgraded Date: 12/30/25
• Date: Action: Upgraded 12/30/25

The score is primarily held back by pre-revenue operations with widening losses and accelerating cash burn, which elevates financing risk despite a strong, low-debt balance sheet. Technical signals are soft and the negative P/E with no dividend provides little valuation support.

Positive Factors

Balance Sheet Strength

Near-zero leverage and a materially larger equity base provide durable financial flexibility to fund clinical development, support partnership negotiations, and absorb biotech execution risk. This buffer helps sustain operations across multi-quarter trial milestones without immediate insolvency risk.

Precision Oncology Focus

A concentrated pipeline in targeted small-molecule oncology aligns with structural demand for precision therapies. If clinical progress continues, focused programs like an EGFR inhibitor can capture defined patient segments, enabling clearer go-to-market strategies and partnership interest over multiple quarters.

Low Debt / Financial Flexibility

Minimal indebtedness reduces fixed financing obligations and interest pressure, preserving cash for R&D and trials. This structural low-debt profile increases strategic choices—licensing, partnerships, or staged financings—supporting program advancement over the next several quarters without immediate debt refinancing risk.

Negative Factors

Pre-revenue Operations

With no product revenue, the company depends entirely on capital markets or partners to fund operations. This structural position leaves execution tied to trial progress and financing cycles; absent near-term commercialization, sustaining development requires repeated external funding events.

Accelerating Cash Burn

Rapidly rising cash outflows materially shorten runway and increase the frequency and size of financing needs. Over a 2–6 month horizon this escalates dilution and constrains discretionary spending, forcing prioritization of programs and potentially slowing development timelines if new capital isn't secured.

Widening Net Losses

Substantially larger net losses reflect intensified R&D and operational investment ahead of any revenue. Persistently negative returns on equity raise the likelihood of additional financings or program cuts, increasing execution and dilution risk and pressuring long-term shareholder returns absent clinical success.

ArriVent BioPharma, Inc. Business Overview & Revenue Model

Company Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

How the Company Makes Money

ArriVent BioPharma, Inc. generates revenue through the development and commercialization of its proprietary drug candidates. The company's key revenue streams include licensing agreements with other pharmaceutical companies, sales of its approved therapies, and potential milestone payments and royalties from its strategic partnerships. These partnerships often involve collaborations for research and development, as well as co-commercialization opportunities, allowing ArriVent to expand its market reach and accelerate product development.

ArriVent BioPharma, Inc. Financial Statement Overview

Summary

Balance sheet strength (near-zero leverage and meaningfully higher equity base) supports flexibility, but financial performance is constrained by being pre-revenue with widening losses and sharply higher cash burn in TTM, increasing dependence on external funding.

Income Statement

AVBP is still pre-revenue (revenue is 0 across annual periods and TTM (Trailing-Twelve-Months)), with persistent operating losses. Losses have widened materially from 2022–2024 and further in TTM (Trailing-Twelve-Months) (net loss ~$151M vs. ~$80M in 2024), indicating accelerating spend ahead of commercialization. A positive is the growing equity base over time, but the income profile remains highly dependent on future pipeline success rather than current operating performance.

Balance Sheet

The balance sheet is a clear strength: leverage is negligible (debt-to-equity is near zero in every period, with only ~$56K of debt in TTM (Trailing-Twelve-Months)). Stockholders’ equity has increased meaningfully from ~$41M (2021) to ~$305M (TTM (Trailing-Twelve-Months)), supporting financial flexibility. The key weakness is negative returns on equity driven by ongoing losses, which will continue to pressure equity if cash burn persists.

Cash Flow

Cash generation is weak, with operating and free cash flow negative in every period and worsening in TTM (Trailing-Twelve-Months) (about -$146M vs. -$70M in 2024), signaling a rising cash burn rate. Free cash flow has been volatile (negative in most years, with a reported rebound in TTM (Trailing-Twelve-Months)), but the absolute level remains deeply negative. The primary risk is that continued burn will require additional funding before revenue ramps.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-156.85M	-80.49M	-74.59M	0.00	-51.61M
Net Income	-151.40M	-80.49M	-69.33M	-36.91M	-51.61M
Balance Sheet
Total Assets	326.56M	274.94M	163.10M	182.83M	43.04M
Cash, Cash Equivalents and Short-Term Investments	300.27M	218.86M	150.39M	163.37M	37.28M
Total Debt	56.00K	176.00K	317.00K	139.00K	0.00
Total Liabilities	21.56M	17.29M	11.80M	8.37M	1.82M
Stockholders Equity	305.00M	257.65M	151.30M	174.46M	41.22M
Cash Flow
Free Cash Flow	-146.08M	-70.21M	-55.84M	-43.63M	-12.59M
Operating Cash Flow	-146.08M	-70.21M	-55.84M	-43.63M	-12.59M
Investing Cash Flow	-192.49M	-192.47M	0.00	0.00	-40.00M
Financing Cash Flow	168.39M	186.58M	42.86M	169.72M	89.87M

ArriVent BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.97
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVBP, the sentiment is Positive. The current price of 22.97 is above the 20-day moving average (MA) of 22.52, above the 50-day MA of 22.04, and above the 200-day MA of 20.91, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 53.80 is Neutral, neither overbought nor oversold. The STOCH value of 50.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVBP.

ArriVent BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RLAY	60 Neutral	$1.83B	-6.36	-41.14%	―	-16.50%	33.02%
IOVA	59 Neutral	$1.59B	-3.44	-55.50%	―	175.62%	19.63%
TSHA	53 Neutral	$1.24B	-12.78	-64.93%	―	-36.36%	-945.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVA	47 Neutral	$1.34B	-1.59	―	―	-12.52%	-82.84%
QURE	46 Neutral	$962.87M	-3.56	-165.27%	―	-44.90%	11.49%
AVBP	45 Neutral	$948.23M	-5.42	-51.98%	―	―	-75.31%